The Food and Drug Administration has approved the first-ever vaccine to combat severe respiratory syncytial virus, or RSV, in older adults, giving your patients 60 and older another level of protection.

According to trial data, Arexvy, developed by GlaxoSmithKline, was 82% effective at preventing lower respiratory tract illness caused by RSV and 94% effective in those who had at least one underlying medical condition.

RSV infects nearly everyone by age 2 and is the leading cause of hospitalizations among newborns and younger children; it also strikes late in life, causing more than 177,000 hospitalizations and 14,000 deaths among older adults each year.

Read the full article here.